Gender, Racial, and Geographical Disparities in Malignant Brain Tumor Mortality in the USA.

IF 2.5 3区医学 Q3 ONCOLOGY Oncology Pub Date : 2024-01-01 Epub Date: 2024-01-27 DOI:10.1159/000536486

Jia Yi Tan, Jia Yean Thong, Yong Hao Yeo, Kelly Mbenga, Sabera Saleh

{"title":"Gender, Racial, and Geographical Disparities in Malignant Brain Tumor Mortality in the USA.","authors":"Jia Yi Tan, Jia Yean Thong, Yong Hao Yeo, Kelly Mbenga, Sabera Saleh","doi":"10.1159/000536486","DOIUrl":null,"url":null,"abstract":"Introduction: Malignant brain tumors are malignancies which are known for their low survival rates. Despite advancements in treatments in the last decade, the disparities in malignant brain cancer mortality among the US population remain unclear.Methods: We analyzed death certificate data from the US CDC WONDER from 1999 to 2020 to determine the longitudinal trends of malignant brain tumor mortality. Malignant brain tumor (ICD-10 C71.0-71.9) was listed as the underlying cause of death. Age-adjusted mortality rates (AAMRs) per 100,000 individuals were calculated by standardizing the AAMR to the year 2000 US population.Results: From 1999 to 2020, there were 306,375 deaths due to malignant brain tumors. The AAMR decreased from 5.57 (95% CI, 5.47-5.67) per 100,000 individuals in 1999 to 5.40 (95% CI, 5.31-5.48) per 100,000 individuals in 2020, with an annual percent decrease of -0.05 (95% CI, -0.22, 0.12). Whites had the highest AAMR (6.05 [95% CI, 6.02-6.07] per 100,000 individuals), followed by Hispanics (3.70 [95% CI, 3.64-3.76]) per 100,000 individuals, blacks (3.09 [95% CI, 3.04-3.14] per 100,000 individuals), American Indians (2.82 [95% CI, 2.64-3.00] per 100,000 individuals), and Asians (2.44 [95% CI, 2.38-2.50] per 100,000 individuals). The highest AAMRs were reported in the Midwest region (5.58 [95% CI, 5.54-5.62] per 100,000 individuals) and the rural regions (5.66 [95% CI, 5.61-5.71] per 100,000 individuals).Conclusions: Our study highlights the mortality disparity among different races, geographic regions, and urbanization levels. The findings underscore the importance of addressing the disparities in malignant brain tumors that existed among males, white individuals, and rural populations.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"703-709"},"PeriodicalIF":2.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000536486","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Malignant brain tumors are malignancies which are known for their low survival rates. Despite advancements in treatments in the last decade, the disparities in malignant brain cancer mortality among the US population remain unclear.

Methods: We analyzed death certificate data from the US CDC WONDER from 1999 to 2020 to determine the longitudinal trends of malignant brain tumor mortality. Malignant brain tumor (ICD-10 C71.0-71.9) was listed as the underlying cause of death. Age-adjusted mortality rates (AAMRs) per 100,000 individuals were calculated by standardizing the AAMR to the year 2000 US population.

Results: From 1999 to 2020, there were 306,375 deaths due to malignant brain tumors. The AAMR decreased from 5.57 (95% CI, 5.47-5.67) per 100,000 individuals in 1999 to 5.40 (95% CI, 5.31-5.48) per 100,000 individuals in 2020, with an annual percent decrease of -0.05 (95% CI, -0.22, 0.12). Whites had the highest AAMR (6.05 [95% CI, 6.02-6.07] per 100,000 individuals), followed by Hispanics (3.70 [95% CI, 3.64-3.76]) per 100,000 individuals, blacks (3.09 [95% CI, 3.04-3.14] per 100,000 individuals), American Indians (2.82 [95% CI, 2.64-3.00] per 100,000 individuals), and Asians (2.44 [95% CI, 2.38-2.50] per 100,000 individuals). The highest AAMRs were reported in the Midwest region (5.58 [95% CI, 5.54-5.62] per 100,000 individuals) and the rural regions (5.66 [95% CI, 5.61-5.71] per 100,000 individuals).

Conclusions: Our study highlights the mortality disparity among different races, geographic regions, and urbanization levels. The findings underscore the importance of addressing the disparities in malignant brain tumors that existed among males, white individuals, and rural populations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

美国恶性脑肿瘤死亡率的性别、种族和地域差异。

导言恶性脑肿瘤是一种以存活率低而闻名的恶性肿瘤。尽管近十年来治疗手段不断进步，但美国人口中恶性脑肿瘤死亡率的差异仍不明确。方法我们分析了美国疾病预防控制中心 WONDER 从 1999 年到 2020 年的死亡证明数据，以确定恶性脑肿瘤死亡率的纵向趋势。恶性脑肿瘤（ICD-10 C71.0-71.9）被列为基本死因。通过将年龄调整死亡率（AAMR）标准化为 2000 年美国人口，计算出每 10 万人的年龄调整死亡率（AAMR）。结果从 1999 年到 2020 年，共有 306375 人死于恶性脑肿瘤。AAMR从1999年的每10万人5.57例（95% CI，5.47 - 5.67）下降到2020年的每10万人5.40例（95% CI，5.31 - 5.48），年下降率为-0.05（95% CI，-0.22，0.12）。白人的急性心肌梗死死亡率最高（每 10 万人 6.05 [95% CI，6.02-6.07]），其次是西班牙裔（每 10 万人 3.70 [95% CI，3.64-3.76]）、黑人（每 10 万人 3.09 [95% CI, 3.04-3.14] per 100,000 individuals）、美洲印第安人（2.82 [95% CI, 2.64-3.00] per 100,000 individuals）和亚洲人（2.44 [95% CI, 2.38-2.50] per 100,000 individuals）。中西部地区（每 10 万人 5.58 [95% CI，5.54-5.62]）和农村地区（每 10 万人 5.66 [95% CI，5.61-5.71]）的急性心肌梗死死亡率最高。）结论我们的研究强调了不同种族、地理区域和城市化水平之间的死亡率差异。研究结果强调了解决恶性脑肿瘤在男性、白人和农村人口中存在的差异的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.